{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:51:02Z","timestamp":1761540662704},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,9,26]],"date-time":"2005-09-26T00:00:00Z","timestamp":1127692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Shear influences platelet aggregate formation and stability, as well as the inhibitory capacities of antithrombotic drugs. We compared the inhibitory and disaggregating properties of two distinct <jats:italic>\u03b1<\/jats:italic>IIb<jats:italic>\u03b2<\/jats:italic>3 antagonists, Abciximab and Lamifiban, on platelet aggregation induced by adenosine diphosphate (ADP) (5\u2003<jats:italic>\u03bc<\/jats:italic>mol\/l) in platelet\u2010rich plasma (PRP), in an aggregometer (poorly defined low shear, &lt;100\/s) and in a microcouette at arterial shear rate (1000\/s). Platelet aggregation was detected by changes in light transmission in the aggregometer (TA), and by particle counting with a flow cytometer (PA). Lamifiban (1\u2003<jats:italic>\u03bc<\/jats:italic>mol\/l) completely inhibited TA or PA induced by ADP in citrated PRP in the aggregometer or microcouette. In contrast, Abciximab (2\u2003<jats:italic>\u03bc<\/jats:italic>mol\/l) only partially inhibited PA in the microcouette while blocking both TA and PA in the aggregometer. Moreover, Abciximab did not reverse platelet aggregates formed either in the microcouette or in the aggregometer, whereas Lamifiban caused complete reversal. On the contrary, Abciximab completely inhibited platelet aggregation induced by ADP in hirudin\/<jats:sc>d<\/jats:sc>\u2010Phe\u2013Pro\u2013Arg\u2013chloromethylketone PRP in the microcouette. Our results demonstrate a marked dependence of inhibitory capacity of Abciximab on shear conditions, with citrate anticoagulant responsible for the residual aggregation, in contrast to Lamifiban, another <jats:italic>\u03b1<\/jats:italic>IIb<jats:italic>\u03b2<\/jats:italic>3 antagonist interacting with a distinct site on <jats:italic>\u03b2<\/jats:italic>3.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05782.x","type":"journal-article","created":{"date-parts":[[2005,9,26]],"date-time":"2005-09-26T14:32:49Z","timestamp":1127745169000},"page":"348-355","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Inhibition and reversal of platelet aggregation by <i>\u03b1<\/i>IIb<i>\u03b2<\/i>3 antagonists depends on the anticoagulant and flow conditions: differential effects of Abciximab and Lamifiban"],"prefix":"10.1111","volume":"131","author":[{"given":"Mony","family":"Frojmovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Labarthe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,10,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404201101"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.2.212"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07442-1"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010091200"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111931"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-0037-1616241","article-title":"Anti\u2010GPIIbIIIa drugs: current strategies and future directions","volume":"86","author":"Coller B.S.","year":"2001","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110973"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood.V68.3.783.783","article-title":"Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb\/IIIa receptor in an experimental animal model","volume":"68","author":"Coller B.S.","year":"1986","journal-title":"Blood"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90551-7"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(00)00385-6"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(98)70240-6"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1055\/s-0038-1656007","article-title":"Surface\u2010secreted von Willebrand factor mediates aggregation of ADP\u2010activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb\u2010IIIa","volume":"77","author":"Frojmovic M.M.","year":"1997","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI973"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.02.059"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(98)70241-8"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)90479-6"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.8.4633"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0830fje"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.08.011"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1055\/s-0037-1616101","article-title":"Complementary roles for fibrin(ogen), thrombospondin and vWF in mediating shear\u2010dependent aggregation of platelets stimulated at threshold thrombin concentrations","volume":"86","author":"Kasirer\u2010Friede A.","year":"2001","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00391-6"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3483"},{"key":"e_1_2_6_24_1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1055\/s-0037-1615618","article-title":"Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb\/IIIa antagonists abciximab, eptifibatide and tirofiban","volume":"85","author":"Marciniak S.J.","year":"2001","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_6_25_1","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1055\/s-0037-1613127","article-title":"An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates","volume":"87","author":"Marciniak S.J.","year":"2002","journal-title":"Thrombosis and Haemostasis"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(00)00150-4"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3882"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.96.5.1488"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1102-1227"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81607-4"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0021-9258(18)54042-4","article-title":"Design of potent and specific antagonists: peptide antagonists with high specificity for glycoprotein IIb\u2010IIIa","volume":"268","author":"Scarborough R.M.","year":"1993","journal-title":"Journal of Biological Chemistry"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.12.3340"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3495(94)81015-X"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.445980.x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05782.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05782.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T14:45:08Z","timestamp":1697381108000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05782.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,17]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05782.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05782.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,17]]},"assertion":[{"value":"2005-10-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}